PBS Biotech

PBS Biotech was founded in 2006 with a vision to transform how cell therapies are developed and manufactured. The company's founders recognized that traditional stirred-tank bioreactors were failing to meet the unique demands of cultivating shear-sensitive therapeutic cells like induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs). So they engineered the Vertical-Wheel® bioreactor - a revolutionary single-use system that provides superior mixing performance, scalability from 0.1L to 80L, and enhanced cell viability compared to conventional technologies.

Today, PBS Biotech stands as a leader in the allogeneic cell therapy market, enabling researchers and manufacturers to streamline their journey from benchtop R&D through clinical trials to commercial-scale production. The company's 63,800 sq. ft. facility in Camarillo, California houses both manufacturing operations and an onsite laboratory where their Bioprocess R&D team delivers world-class contract process development services. With over $47 million in funding from investors including Avego Management and BroadOak Capital Partners, and recognition as Single-Use Bioreactors Company of the Year 2025, PBS Biotech continues to advance its mission of enabling life-saving therapies for cancer, diabetes, heart failure, and other critical diseases.